Page 1

Press Release dated December 15 , 2021 Trinity Biotech Contact : Trinity Biotech plc John Gillard ( 353 ) -1-2769800 Lytham Partners , LLC Joe Diaz ( 1 ) -602-889-9700 E - mail : investorrelations@trinitybiotech.com Trinity Biotech Announces Q3 2021 Results , the Entry Into a $ 81,250,000 Loan Facility to Refinance the Company's Exchangeable Senior Notes and Agreements To Repurchase Outstanding Exchangeable Senior Notes DUBLIN , Ireland ( December 15 , 2021 ) .... Trinity Biotech plc ( Nasdaq : TRIB ) ( the " Company " ) , a leading developer and manufacturer of diagnostic products for the point - of - care and clinical laboratory markets , today announced results for the quarter ended September 30 , 2021 , the entry into a $ 81.25million loan facility to refinance the existing $ 99.9million of exchangeable senior notes issued by the Company's subsidiary , Trinity Biotech Investment Limited ( the “ Notes ” ) , and exchange agreements for over 99.7 % of the outstanding Notes , all subject to certain conditions precedent . Quarter 3 2021 Results Total revenues for Q3 , 2021 were $ 22.0m , which compares to $ 32.0m in Q3 , 2020 , a decrease of $ 10.0m and which were broken down as follows : Point - of - Care Clinical Laboratory Total 2020 Quarter 3 2021 Quarter 3 Increase / ( decrease ) US $ ' 000 US $ ' 000 % 2,065 4,113 99.2 % 29,949 17,891 ( 40.3 % ) 32,014 22,004 ( 31.3 % ) Point - of - Care revenues for Q3 , 2021 increased from $ 2.1m to $ 4.1m when compared to Q3 , 2020 , an increase of 99.2 % . This increase was attributable to higher HIV revenues from Africa related sales . Revenues in Q3 2020 had been negatively impacted by logistical constraints caused by the pandemic . While the situation somewhat improved in 2021 , COVID - 19 continues to have the potential to cause disruption to HIV testing in Africa . Clinical Laboratory revenues decreased from $ 30.0m to $ 17.9m , which represents a decrease of 40.3 % compared to Q3 , 2020. The decrease is mainly due to lower revenues from within our COVID- 19 related portfolio of products . In Q3 2020 , demand for PCR Viral Transport Media ( " VTM " ) products was exceptional while there was limited worldwide manufacturing capacity . As the pandemic has persisted , manufacturing capacity has ramped up significantly with a consequent negative impact on selling prices . As stated previously , the Company noted a significant reduction in demand for new orders of VTM from early 2021 as COVID - 19 testing volumes dropped and customers utilised stockpiled product . While the situation relating to COVID - 19 products remains very fluid , with the evolving impact of